XenoPort can give no assurance with respect to these statements and we assume no obligation to update them. For detailed information about the risks and uncertainties that could cause actual results to differ materially from those implied by or anticipated in these forward-looking statements, please refer to the Risk Factor section of our most recent SEC filings, including our discussion of the inherent risks of clinical trials and regulatory matters. This webcast is a copyright of XenoPort.At this time, I will turn the presentation over to Ron. Ron Barrett Thank you, Jackie. Good afternoon and thank you to those joining us on today’s call. I would like to discuss our progress since the last quarterly call and then Bill Harris will discuss the highlights of our second quarter financial results. We will both be relatively brief and then we will then take your questions. We have been busy since the start of the second quarter and I’d like to thanks Xenoport’s employees for their strong efforts in advancing multiple development programs and other business objectives. Starting with our novel fumarate compound, 829, we initiated the first human trial two weeks ago. We expect dosing of the 60 healthy volunteer subjects in this single dose fed versus fasted Phase 1 trial four formulations of 829 plus placebo will be completed this week. We will have a lot of bioanalytical work to complete and we hope to report preliminary safety, tolerability, pharmacokinetic results from this trial in October. As you know, we are interested in the potential development of 829 in relapsing-remitting multiple sclerosis or RRMS and psoriasis. In addition to these two potential indications, there are published data that suggest potential utility of Nrf2 activator in a number of neurodegenerative diseases. In July, we were happy to announce the collaboration with the Michael J. Fox Foundation that will enable us to assess 829’s potential efficacy in the Parkinson's disease animal model.
Now turning to Arbaclofen Placarbil or AP, we expect completion of enrollment of the pivotal Phase 3 trial for the treatment of spasticity in MS patients this fall and topline results in Q1 of 2013. Patients who complete this trial are eligible to continue AP treatment in the six-month open-label safety study.As I mentioned in our last call, we initiated communication with the FDA to discuss the possible need to modify our trials to ensure that we meet the FDA's safety data requirements of 150 subjects with six months and 100 subjects with nine months of AP exposure. We now have FDA agreement to enroll subjects directly into the open-label safety study, allowing directly enroll subjects to stay on AP for nine months. We believe that this was a good outcome since it avoided potential modification of the Phase 3 efficacy protocol for which we have a special protocol assessment and should allow us to keep our timeline of the potential filing of the NDA in the second half of 2013. In June, we also had a productive End-of-Phase 2 meeting with the FDA, regarding our L-Dopa prodrug 279. As I mentioned last quarter, we have discussed the data with of our Phase 2 279 trial with an advisory board comprised of Parkinson's disease experts. They indicated they believe that the pharmacokinetics of 279 compared to Sinemet were impressive, encouraged us to find a way and continue development of product candidate. We also took note of the results of the Phase 3 trial of the intravenous infusion pump Duodopa, that were presented at AAN earlier this year, where the maximum benefit of Duodopa over optimized Sinemet was observed at 10 to 12 weeks. I’ll remind you that the length of treatment of the optimized doses of 279 and Sinemet in the randomize phase of our Phase 2 trial was only two weeks. Read the rest of this transcript for free on seekingalpha.com